Home » Stocks » NSPR

InspireMD Inc. (NSPR)

Stock Price: $0.879 USD -0.021 (-2.33%)
Updated Feb 26, 2021 1:18 PM EST - Market open
Market Cap 103.80M
Revenue (ttm) 3.34M
Net Income (ttm) -9.25M
Shares Out 34.88M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE 11.70
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $0.879
Previous Close $0.900
Change ($) -0.021
Change (%) -2.33%
Day's Open 0.890
Day's Range 0.820 - 0.925
Day's Volume 7,086,875
52-Week Range 0.282 - 1.480

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carot...

GlobeNewsWire - 2 weeks ago

TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carot...

GlobeNewsWire - 2 weeks ago

TEL AVIV, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet...

GlobeNewsWire - 3 weeks ago

TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet...

GlobeNewsWire - 3 weeks ago

New Chinese Distributor Will Also Invest in At-The-Market Private Placement New Chinese Distributor Will Also Invest in At-The-Market Private Placement

GlobeNewsWire - 1 month ago

TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by c...

Seeking Alpha - 3 months ago

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...

GlobeNewsWire - 3 months ago

TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...

GlobeNewsWire - 3 months ago

Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET

GlobeNewsWire - 4 months ago

TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by c...

GlobeNewsWire - 4 months ago

TEL AVIV, Israel, Oct. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...

GlobeNewsWire - 5 months ago

Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States

GlobeNewsWire - 5 months ago

IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States IDE Approval to Pave the Way for Pivotal Study of CGuard S...

GlobeNewsWire - 5 months ago

TEL AVIV, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused b...

GlobeNewsWire - 6 months ago

TEL AVIV, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...

GlobeNewsWire - 6 months ago

TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...

Seeking Alpha - 6 months ago

InspireMD's (NSPR) CEO Marvin Slosman on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

 In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies t...

GlobeNewsWire - 6 months ago

Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET

GlobeNewsWire - 6 months ago

Conference Call to be held Thursday, August 5, 2020 at 8:30am ET Conference Call to be held Thursday, August 5, 2020 at 8:30am ET

GlobeNewsWire - 8 months ago

In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure In a head-to-head evaluation, significantly ...

GlobeNewsWire - 8 months ago

Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events

GlobeNewsWire - 8 months ago

TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...

GlobeNewsWire - 8 months ago

TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...

Seeking Alpha - 9 months ago

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets

Seeking Alpha - 11 months ago

InspireMD's (NSPR) CEO Marvin Slosman on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS

Zacks Investment Research - 1 year ago

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CVEO, GCO, RDWR, WPRT
Seeking Alpha - 1 year ago

InspireMD, Inc. (NSPR) CEO Jim Barry on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Sept. 19, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused b...

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused b...

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by ca...

Seeking Alpha - 1 year ago

InspireMD, Inc. (NSPR) CEO Jim Barry on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

InspireMD (NSPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

InspireMD, Inc. (NSPR) CEO Jim Barry on Q1 2019 Results - Earnings Call Transcript

About NSPR

InspireMD, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard... [Read more...]

Industry
Medical Devices
CEO
Alan Milinazzo
Employees
48
Stock Exchange
NYSEAMERICAN
Ticker Symbol
NSPR
Full Company Profile

Financial Performance

In 2019, InspireMD's revenue was $3.72 million, an increase of 3.33% compared to the previous year's $3.60 million. Losses were -$10.04 million, 38.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for InspireMD stock is "Buy." The 12-month stock price forecast is 0.85, which is a decrease of -3.30% from the latest price.

Price Target
$0.85
(-3.30% downside)
Analyst Consensus: Buy